# PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)

> **NCT02074436** · PHASE2 · TERMINATED · sponsor: **Emory University** · enrollment: 29 (actual)

## Conditions studied

- Hematological Malignancies
- Thrombocytopenia

## Interventions

- **DRUG:** EACA
- **OTHER:** Platelet transfusion

## Key facts

- **NCT ID:** NCT02074436
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-05-23
- **Primary completion:** 2020-11-24
- **Final completion:** 2021-05-14
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02074436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02074436, "PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02074436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*